Drug Pricing

Drug Prices

Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance

Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV. 

Commentary

Government Drug Price Negotiations Offer A False Promise

With inflation rising and midterm elections just months away, Democrats are desperate for something they can pitch to voters as a reason to keep them in control of Congress. They’re hoping a watered-down version of their Build Back Better Act could do the trick. Sen. Joe Manchin, D-W. Va., who helped shoot the bill …

Business & Economics

Rounding Up The Usual Suspects Won’t Alleviate Inflation

Doing his best Captain Renault impersonation, President Biden is trying to alleviate the troubling inflationary environment by “rounding up the usual suspects”. In this case, that means blame a problem that can only be caused by errant government policies on politically convenient targets such as rising drug prices, Russia’s invasion of the …

Commentary

Where’s The Promised Transparency in Drug Pricing?

Hospitals are shoring up their balance sheets on the backs of cancer patients, according to a new study published in JAMA Internal Medicine. Researchers looked at 25 of the top cancer medications distributed at 61 cancer treatment centers across the country over the course of six months. They found that …

Commentary

Facts, Economic Reason No Match for Left’s Drug Pricing Fixation

Last week, the U.S. Senate Finance Committee held a hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” It’s rare to see so many falsehoods in so few words. The idea that drug-price inflation is especially bad or that it poses some sort of threat to …

Commentary

Drug Pricing Reforms Should Expand Choice, Not Government Control

As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress …

Blog

Biden’s Non-Plan for Fighting Inflation

In a recent survey, Americans ranked inflation as the most urgent issue facing the country.  So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address.  After listening to his speech, you can’t help but think that …

Commentary

Light starts to shine on opaque drug pricing tactics

Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with …

Commentary

High Healthcare Spending Doesn’t Bolster Case for Single-Payer

Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of …

Drug Pricing

Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News

Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.

Drug Prices

Sally Pipes Discusses Prescription Drugs and Inflation Reduction Act on Eric Bolling: The Balance

Watch PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy discuss prescription drug costs and the so-called Inflation Reduction Act on “Eric Bolling: The Balance” on Newsmax TV. 

Commentary

Government Drug Price Negotiations Offer A False Promise

With inflation rising and midterm elections just months away, Democrats are desperate for something they can pitch to voters as a reason to keep them in control of Congress. They’re hoping a watered-down version of their Build Back Better Act could do the trick. Sen. Joe Manchin, D-W. Va., who helped shoot the bill …

Business & Economics

Rounding Up The Usual Suspects Won’t Alleviate Inflation

Doing his best Captain Renault impersonation, President Biden is trying to alleviate the troubling inflationary environment by “rounding up the usual suspects”. In this case, that means blame a problem that can only be caused by errant government policies on politically convenient targets such as rising drug prices, Russia’s invasion of the …

Commentary

Where’s The Promised Transparency in Drug Pricing?

Hospitals are shoring up their balance sheets on the backs of cancer patients, according to a new study published in JAMA Internal Medicine. Researchers looked at 25 of the top cancer medications distributed at 61 cancer treatment centers across the country over the course of six months. They found that …

Commentary

Facts, Economic Reason No Match for Left’s Drug Pricing Fixation

Last week, the U.S. Senate Finance Committee held a hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” It’s rare to see so many falsehoods in so few words. The idea that drug-price inflation is especially bad or that it poses some sort of threat to …

Commentary

Drug Pricing Reforms Should Expand Choice, Not Government Control

As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress …

Blog

Biden’s Non-Plan for Fighting Inflation

In a recent survey, Americans ranked inflation as the most urgent issue facing the country.  So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address.  After listening to his speech, you can’t help but think that …

Commentary

Light starts to shine on opaque drug pricing tactics

Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with …

Commentary

High Healthcare Spending Doesn’t Bolster Case for Single-Payer

Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of …

Drug Pricing

Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News

Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.

Scroll to Top